1. A teapot folded from a sheet, the sheet comprising:
a pot bottom portion;
a plurality of pot wall portions, the pot wall portions surrounding and connected with the pot bottom portion, the pot wall portions and the pot bottom portion are seamless;
a plurality of folding portions for connecting the pot wall portions which are adjacent to each other respectively, and folded to make the pot wall portions to form a pot body, one of the folding portions extending to outside of the pot body to form a spout; and
a pot lid portion connected with one of the pot wall portions.
2. The teapot according to claim 1, wherein the folding portions and the pot wall portions are seamless.
3. The teapot according to claim 1, wherein one of the folding portions extends to outside of the pot body to form a handle.
4. The teapot according to claim 1, wherein one of the folding portions extends to be attached to one of the pot wall portions.
5. The teapot according to claim 1, wherein part of the folding portion extending to outside of the pot body to form the spout is attached to one of the pot wall portions.
6. The teapot according to claim 1, wherein the teapot has a first folding line for storage, and the teapot is foldable along the first folding line.
7. The teapot according to claim 1, further comprising:
a thermochromic ink pattern disposed at an outer surface of the sheet.
8. A disposable tea set comprising:
a teapot folded from a first sheet, the first sheet including:
a pot bottom portion;
a plurality of pot wall portions, the pot wall portions surrounding and connected with the pot bottom portion, the pot wall portions and the pot bottom portion are seamless;
a plurality of folding portions for connecting the pot wall portions which are adjacent to each other respectively, and folded to make the pot wall portions to form a pot body, one of the folding portions extending to outside of the pot body to form a spout; and
a pot lid portion connected with one of the pot wall portions; and
a teacup folded from a second sheet and accommodated in the teapot.
9. The disposable tea set according to claim 8, wherein the folding portions and the pot wall portions are seamless.
10. The disposable tea set according to claim 8, wherein one of the folding portions extends to outside of the pot body to fonn a handle.
11. The disposable tea set according to claim 8, wherein one of the folding portions extends to be attached to one of the pot wall portions.
12. The disposable tea set according to claim 8, wherein part of the folding portion extending to outside of the pot body to form the spout is attached to one of the pot wall portions.
13. The disposable tea set according to claim 8, wherein the teapot has a folding line for storage, and the teapot is foldable along the folding line.
14. The disposable tea set according to claim 8, further comprising:
a fastening tape surrounding the teapot.
15. The disposable tea set according to claim 8, further comprising:
a thermochromic ink pattern disposed at an outer surface of the first sheet or an outer surface of the second sheet.
16. The disposable tea set according to claim 8, further comprising:
a tea bag accommodated in the teapot.
17. The disposable tea set according to claim 16, wherein the tea bag is connected with the pot lid portion.
18. The disposable tea set according to claim 8, wherein the teacup has a second folding line for storage, and the teacup is foldable along the second folding line.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
We claim:
1. A composition that comprises (a) an agent that attenuates CD1d-restricted NK T cells responses, wherein the agent is selected from the group consisting of antagonists that bind CD1d and inhibit activation of CD1d-restricted NK T cells, agents that block CD1d-specific receptors and CD1d decoys and (b) a pharmaceutically acceptable carrier or diluent.
2. The composition of claim 1, wherein the composition is adapted for topical administration.
3. The composition of claim 1, wherein the agent is a phospholipid that binds CD1d without activating NK T cells.
4. The composition of claim 4, wherein the phospholipid is selected from the group consisting of 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine (DPPE), 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N-Poly(ethylene glycol) 2000 (DPPE-PEG), and phophotidyl inositol.
5. The composition of claim 1, wherein the agent is a glycolipid.
6. The composition of claim 5, wherein the glycolipid is selected from the group consisting of ceramide, Man Cer, and Gal Cer.
7. A method of attenuating CD1d-restricted NK T cells responses, comprising administering to a subject a composition that comprises an agent that attenuates CD1d-restricted NK T cells responses, wherein the agent is selected from the group consisting of antagonists that bind CD1d and inhibit activation of CD1d-restricted NK T cells, agents that block CD1d-specific receptors on NK T cells, and decoys and mimics.
8. The method of claim 7, wherein the CD1d-restricted NK T cells responses are associated with skin disorders due to hyperactive CD1d-restricted T cell responses and other disorders associated with ongoing CD1d-restricted immune responses.
9. The method of claim 8, wherein the skin disorders include contact dermatitis and further eczematous dermatitises, atopical dermatitis, seborrheic dermatitis, Lichen planus, Pemphigus, bullous Pemphigoid, epidermolysis bullosa, urticaria, angioedemas, vasculitides, erythemas, cutaneous eosinphilias, Lupus erythematosus, and Alopecia areata.
10. The method of claim 7, wherein the CD1d-restricted NK T cells responses are associated with psoriasis.
11. The method of claim 8, wherein the skin disorder is contact dermatitis.
12. The method of claim 7, wherein the composition is present in a pharmaceutical composition, moisturizing composition or a cosmetic composition.
13. The composition of claim 7, wherein the agent is a phospholipid that binds CD1d without activating NK T cells.
14. The composition of claim 13, wherein the phospholipid is selected from the group consisting of 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine (DPPE) and 1,2-Dipalmitoyl-sn-Glycero-3-Phosphoethanolamine-N-Poly(ethylene glycol) 2000 (DPPE-PEG).
15. The composition of claim 7, wherein the agent is a glycolipid.
16. The composition of claim 15, wherein the glycolipid is selected from the group consisting of ceramide, Man Cer, and Gal Cer.
17. A method of preventing or reducing a CD1d-restricted NK T cells’ responses, comprising administering to a subject prior to exposure to an irritant a composition that comprises an agent that attenuates CD1d-restricted NK T cells responses, wherein the agent is selected from the group consisting of antagonists that bind CD1d and inhibit activation of CD1d-restricted NK T cells, agents that block CD1d-specific receptors on NK T cells, and decoys and mimics.
18. The method of claim 17, wherein the irritant is selected from the group consisting of poison ivy, poison oak, poison sumac, insecticides, dye intermediates, resins, detergents, antioxidants, rubber, latex, metals, fragrances, chemicals, cosmetics, textiles, plastics, pollen, therapeutic agents, skin cleansers, industrial cleaning agens, alkalis, acids, oils, organic solvents, oxidizing agents, reducing agents, plant matter, and animal matter.
19. The method of claim 7, wherein the composition is administered by topical administration.
20. The method of claim 7, wherein the composition is administered by systemic administration.
21. The method of claim 20, wherein the compositions are administered to a subject with an autoimmune disease such as lupus or at high risk for spontaneously aborting pregnancies.
22. A method of preventing andor inhibiting a CD1d associated skin disorder comprising administering to a subject at risk for the activated CD1d associated skin disorder, an effective amount of the compound of claim 1.
23. The method of claim 22, wherein the CD1d associated skin disorder is selected from the group consisting of contact dermatitis, eczematous dermatitises, atopical dermatitis, seborrheic dermatitis, Lichen planus, Pemphigus, bullous Pemphigoid, epidermolysis bullosa, urticaria, angioedemas, vasculitides, erythemas, cutaneous eosinphilias, Lupus erythematosus, psoriasis and Alopecia areata.